A new study has identified polyphosphate as a likely "mystery density" within fibrils associated with Alzheimer's and other ...

Learn about early-onset Alzheimer's through real stories of hope and breakthrough treatments that are changing lives of patients diagnosed before age ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

When we think about dementia, we often think of a person experiencing memory loss and confusion. While it’s true that these ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...

Research reveals how herpes simplex virus-1 may contribute to Alzheimer’s disease, offering new insights into the disease’s ...

There is a potential link between Alzheimer's disease and the herpes simplex virus-1 (HSV-1), which is a common cause for ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...